Clinical effect of combined finasteride and metformin treatment for benign prostatic hyperplasia plus diabetes mellitus
10.3760/cma.j.issn.0254-9026.2012.11.002
- VernacularTitle:非那雄胺联合二甲双胍治疗老年人良性前列腺增生并糖尿病临床疗效分析
- Author:
Xiaoxiang YU
;
Shian HE
;
Shiwu CHEN
;
Daqing ZHOU
;
Zengnan MO
;
Qiang WANG
;
Ruiming ZHANG
;
Wengang LI
;
Bo JIANG
;
Shangwen LIU
;
Jian WANG
;
Changjie YU
;
Meng HE
;
Xiang PANG
- Publication Type:Journal Article
- Keywords:
Prostatic hyperplasia;
Diabetes mellitus,type 2;
Finasteride;
Metformin
- From:
Chinese Journal of Geriatrics
2012;31(11):932-934
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficiency of combined finasteride and metformin on benign prostatic hyperplasia (BPH) with type 2 diabetes mellitus(T2DM).Methods Totally 106 patients with BPH plus T2DM received finasteride and metformin treatment for over 12months.Before and after treatment,the side effects and following parameters were measured:prostatic volume (PV),prostate-specific antigen(PSA),international prostate symptom score (IPSS),quality of life (QOL),the maximum flow rate of urinary (Qmax),residual urine(RU),body mass index (BMI),cholesterol (TG).Results There were obvious changes in the following:PV decreased from (56.40±18.75)ml to(42.40± 19.68) ml,PSA decreased from(3.65± 1.08) μg/L to (1.76±0.66)μg/L,IPSS decreased from(22.58±9.45)to(16.67±7.56),QOL decreased from(4.22± ±0.87) to (2.36 ± 0.74),Qmax increased from(8.32±2.42)ml/s to(15.48±3.61)ml/s,RU decreased form(68.36±19.25)ml to(36.42±13.91)ml,BMI decreased from(28.52±3.73)kg/m2 to (19.76± 1.88)kg/m2,TG decreased from (2.52 ± 0.43) mmol/L to (1.38 ± 0.52) mmol/L.The changes of PV,PSA,IPSS,QOL,Qmax,RU,BMI and TG were statistically significant (all P＜0.05).Conclusions Long term combined finasteride and metformin treatment for BPH plus T2DM is effective and safe.And the two drugs may be improve the efficacy each other.
